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ABSTRACT
Background Relatively few studies have searched for
potentially pathogenic antibodies in non-paraneoplastic
patients with cerebellar ataxia.
Methods and Results We ﬁrst screened sera from 52
idiopathic ataxia patients for binding of serum IgG
antibodies to cerebellar neurons. One strong-binding
serum was selected for immunoprecipitation and mass
spectrometry, which resulted in the identiﬁcation of
contactin-associated protein 2 (CASPR2) as a major
antigen. CASPR2 antibodies were then found by a cell-
based assay in 9/88 (10%) ataxia patients, compared to
3/144 (2%) multiple sclerosis or dementia controls
(p¼0.011). CASPR2 is strongly expressed in the
cerebellum, only partly in association with voltage-gated
potassium channels.
Conclusions Prospective studies are now needed to
see whether identiﬁcation of CASPR2 antibodies has
relevance for the diagnosis and treatment of idiopathic
cerebellar ataxia.
INTRODUCTION
Cerebellar ataxia is a relatively common syndrome
with diverse causes. Some patients have a para-
neoplastic aetiology associated with autoantibodies
to intracellular antigens, such as Yo (PCA-1), but
these antibodies are unlikely to be directly patho-
genic, and the patients seldom respond well to
immunotherapies. In the last few years, antibodies
to neuronal surface antigens have been demon-
strated in patients with immunotherapy-respon-
sive forms of limbic encephalitis and related
disorders,
1 2 raising the possibility that other CNS
disorders may also result from autoantibodies to
cell-surface proteins. There have been some
previous reports of potentially pathogenic anti-
bodies in cerebellar ataxia, such as voltage-gated
calcium channel (VGCC) antibodies,
3 glutamic
acid decarboxylase (GAD) antibodies mainly in
patients with polyendocrine syndromes,
4 a small
number of patients with mGluR1 antibodies,
5 and
associations of cerebellar ataxia with gluten sensi-
tivity and gliadin antibodies,
6 but there have been
few systematic cohort studies to identify new
antigens. Here we have identiﬁed a potentially
pathogenic antibody against the neuronal
membrane protein contactin-associated protein 2
(CASPR2) in nine of 88 (10%) patients with
unexplained ataxia.
SUBJECTS AND METHODS
Clinical material
Twenty-ﬁve Spanish sera (Valencia, 10; Barcelona,
15) were from patients with acute or subacute
cerebellar ataxia (<3 months duration at testing)
referred for onconeural antibody testing, with some
evidence of an autoimmune mechanism (CSF raised
cells or oligoclonal bands, partial response to
immunotherapy and/or spontaneous remission)
but with no serological or imaging evidence of
tumours, and exclusion of other causes including
infectious disorders. We also studied 27 and subse-
quently a further 36 sera from Welsh patients with
idiopathic late onset cerebellar ataxia who had been
recruited to a population-based study in south
Wales between 1999 and 2008 and in whom known
causes or associations (eg, coeliac disease) had been
excluded.
7 All three centres had ethics approval for
the study of these patients’ sera. Control sera
included 101 from patients with multiple sclerosis
and 43 from patients with dementia. Radio-
immunoprecipitation assays were used to look for
antibodies to VGCC, GAD and voltage-gated
potassium channel complexes (VGKC-complex) as
previously described.
348
Antibody-binding assays
Cerebellar organotypic slice cultures were prepared
from 9-day-old mice and dissociated cultures of
cerebellar granule neurons (CGNs) were prepared
from 5-day-old mice as previously described.
9 10
Antibody-binding assays were performed on orga-
notypic slices after 12 days (P9+DIV12) in culture
and on CGNs after 10 days (P5+DIV10). Unﬁxed
slices or neurons were incubated with patient
sera (1:125) in serum-free culture media supple-
mented with 25 mM Hepes and 1% bovine serum
albumin for 1 h at room temperature (RT), washed
three times and ﬁxed with 3% formaldehyde in
phosphate-buffered saline for 30 min (slices) or
15 min (CGNs) at RT. Subsequently, slices were
permeabilised with methanol for 5 min at  208C.
After three washes, slices and CGNs were incu-
bated with anti-human IgG Alexa Fluor 568-
conjugated secondary antibody (Invitrogen,
Carlsbad, California, USA) for 45 min at RT. Slices
were counterstained with an anti-calbindin anti-
body (Swant, Marly, Switzerland) to label Purkinje
neurons. Slices and CGNs were washed and
mounted with mounting medium containing DAPI
(Vectashield; Vector Laboratories, Burlingame,
California, USA).
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Movement disordersThe cell-based assay (CBA) was performed as described.
8
Brieﬂy, human embryonic kidney cells (HEK293T) (American
Type Culture Collection) were transfected with EGFP-tagged
CASPR2. Then, 48 h post-transfection, live cells were incubated
with patient sera initially at 1:50 and subsequently at 1:100 for
1 h at RT and then ﬁxed and stained as described above. Anti-
body binding at 1:100 was visualised using an immunoﬂuores-
cence microscope and scored by at least two independent
blinded observers from 0 to 4 as in previous studies.
11 12 The
ﬁnal score was the median of scores of two to three independent
assays for each serum (variance <1).
Immunoprecipitation and mass spectrometry
Live CGNs in culture (P5+DIV10) were incubated with patient
sera (1:40) in serum-free culture media buffered with 25 mM
Hepes for 30 min at RT. Subsequently, neurons were washed
twice and solubilised with 10 mM Tris pH 7.5, 100 mM NaCl,
1 mM EDTA, 1% TritonX-100 and protease inhibitors for 45 min
rotating at 48C. Samples were centrifuged for 15 min at
maximum speed at 48C, and the supernatants were incubated
with protein A-agarose for 5 h at 48C. The beads were washed
ﬁve times and resuspended in SDS sample buffer, boiled and
analysed by gradient SDS-PAGE (Nupage; Invitrogen) with
Coomassie staining (Imperial Protein Stain; Thermo Scientiﬁc,
Rockford, Illinois, USA). Coomassie-stained bands were
extracted as previously described.
13 Digested protein material
was analysed by liquid chromatography using an Ultimate 3000
nano-HPLC system interfaced with a 3D high capacity ion trap
mass spectrometer (AmaZon; Bruker Daltonics, Billerica,
Massachusetts, USA). Raw LC-MS/MS data were processed
Figure 1 The serum bound strongly, in a punctuate manner, to the axons of cerebellar granule neurons (CGNs) in the molecular layer of
unpermeabilised organotypic cerebellar slices (A) and unpermeabilised dissociated CGN cultures (B). GCL, granule cell layer; ML, molecular layer. (C)
Gel electrophoresis of immunoprecipitates after incubation of serum with unpermeabilised CGNs followed by solubilisation. The asterisks indicate
heavy and light IgG chains, respectively. All precipitated proteins were excised and analysed by mass spectrometry. CASPR2, corresponding to the
180-kDa protein band selectively precipitated by the patient’s IgG (arrow), was the only signiﬁcant membrane protein identiﬁed by mass spectrometry
(MudPIT scores >41). (D) The index patient serum IgG (red) bound strongly to the CASPR2-EGFP-transfected (green) HEK293T cells (score 4) but the
control serum did not bind (score 0). (E) Binding in the cell-based assay was determined at 1:100 serum dilution and scored visually from 0 (no binding)
to 4 (very strong binding). Sera scoring 1 or above were considered positive, as in our previous publications, and only if scoring 1 or above in two
independent, coded assays. Positive binding to CASPR2 (score 1e4) was detected in nine of 88 (10%) patient sera compared with three of 144 control
samples (Fisher’s exact test, p¼0.011). The horizontal line represents the cut-off above which the results are considered positive. To conﬁrm some of
the lower values, available sera were tested to endpoint dilution. Two MS sera scoring 1 and 2 titrated to 1:100 and 1:200; two ataxia sera scoring 1
and 1.5 titrated to 1:200 and 1:400.
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Movement disordersusing DataAnalysis 3.4 (Bruker Daltonics) and Mascot software
with the SwissProt database.
RESULTS
To identify surface antigens that might mediate autoimmune
cerebellar ataxia, we ﬁrst screened the 25 Spanish and 27 of the
Welsh sera. None had onconeural antibodies, evidence of
a tumour, or an identiﬁable genetic or other cause. One patient
had very high antibodies to GAD (4000 U/ml), four patients had
low levels of antibodies against VGCC (range 84e122 pM,
normal values (nv) <45 pM), and two patients had antibodies to
VGKC-complexes (757 and 165 pM, nv <100 pM).
We tested the 52 sera for IgG binding to live, unpermeabilised
cerebellar neurons using organotypic cerebellar slice cultures and
dissociated primary CGNs. We identiﬁed 14 sera that showed
positive staining on cerebellar neurons and no signiﬁcant binding
with seven healthy sera, all observed in a blinded manner. We
focused on the serum that bound most strongly in a punctate
manner to the axons of the CGNs in the molecular layer of the
slices and to dissociated CGNs (ﬁgure 1A,B). To identify the
neuronal surface proteins recognised by the patient serum IgG,
we performed an immunoprecipitation from the granule neuron
cultures using this patient’s and one healthy control serum. A
180-kDa polyprotein was selectively precipitated by the patient
serum (ﬁgure 1C) and identiﬁed as contactin-associated protein
like-2 (CASPR2) by mass spectroscopy. The other distinctive
bands yielded no signiﬁcant hits (data not shown).
To conﬁrm the presence of CASPR2 antibodies in this
patient’s serum, and to test the whole cohort, we employed
a cell-based assay using full-length GFP-tagged human CASPR2
expressed in HEK293Tcells.
8 We scored the binding of the serum
antibodies with a visual scoring system on coded samples that
has been well-validated for other antibodies
11 12 and is used for
routine diagnosis. The index patient serum bound strongly to
the CASPR2 cells (score 4; normal values <1; ﬁgure 1D), but not
to untransfected cells or control-transfected cells (not shown).
An additional six sera (three of those positive on slices) also
bound to CASPR2, with scores between 1 and 3 (total 7/52). We
then tested another 36 ataxia patients and found a further two
CASPR2-antibody positive patients, making a total of 9/88
(10%); one additional patient had VGKC-complex antibodies by
immunoprecipitation (186 pM) but none were positive for GAD
antibodies. Only 3/144 (2%) disease control sera tested in
parallel were positive for CASPR2 antibodies (scores 1e2). All
results are shown in ﬁgure 1E.
Information on the CASPR2-antibody positive patients is
given in table 1. Most had a subacute or insidious onset mainly
with a progressive course, but one with the lowest CASPR2
antibody had an acute onset, fully reversible cerebellar ataxia.
Six of the patient samples were not taken early in the course of
the disease. The index patient, who had the high VGKC-
complex antibody titre of 757 pM, was a man of 59 years of age
whose predominant presenting features were slurred speech,
unstable gait and personality changes, followed by a nocturnal
generalised tonic-clonic seizure. MRI, CSF and EMG were
reported as normal. Although the patient was a heavy smoker,
all tumour screens were negative. He progressively deteriorated
with difﬁculties in phonation, swallowing and walking, as well
as psychiatric disturbance, and probable temporal lobe seizures.
CSF was normal and viral screen negative. By that time, there
were mild FLAIR hyperintensities in both hippocampi, with
mild cerebellar atrophy, and interictal EEG showed bilateral
temporal epileptiform discharges. VGKC-complex antibodies
were ﬁrst found to be positive at this stage, and the patient was
treated with high dose intravenous immunoglobulins with
partial temporary amelioration of symptoms including the
ataxia; cyclosporine was introduced a year later and used for
3 years. When last seen, the patient was stable on lamotrigine
Table 1 Summary of clinical and serological data in eight patients with CASPR2 and/or VGKC-complex antibodies
Patient
Age,
sex
Duration of
disease at
sampling
Onset,
course MRI CSF
Extracerebellar
involvement
Other
autoimmune
diseases
VGKC-
complex
Ab (pM)
CASPR2
Ab score
in CBA
Staining on
cerebellar
slices
07e223 59, F <3 months Subacute,
progressive
Mild cerebellar
atrophy, no temporal
lobe changes
Normal,
OCB neg
Limbic
encephalitis
Thyroid
antibodies
757 4 Pos
06e26 50, F <3 months Subacute,
progressive
Mild atrophy to
severe atrophy
Normal,
OCB not
determined
None Sarcoidosis
(mediastinal
adenopathies),
ANA
<100 3 Pos
02e762 35, F <3 months Acute, full
recovery
Normal NA NA NA <100 1 Neg
A383 54, M 5 years Fast
progressing
NA NA Yes NA <100 2.5 NA
A425 55, F 14 years Subacute,
progressive
Normal Normal None Thyroid
disease
<100 2 Pos
A327 58, F 9 years Chronic,
progressive
Normal ND None No <100 2 Neg
A386 59, F 8 years Chronic,
stable
ND ND None No <100 1 Neg
A220 68, F 9 years Subacute,
progressive
Small vessel
disease
ND Mild
bradykinesia
No <100 1 Pos
A201 76, F NA Acute/
subacute
NA NA NA NA <100 1 NA
The serum samples were obtained either at presentation or after several years. The majority of patients had subacute onset with slowly progressive disease, except for two, who had acute
onset with full recovery. Four additional patients had low positive antibodies against voltage-gated calcium channels (85e122 pM; nv <45 pM), two had VGKC-complex antibodies (186 pM,
168 pM) and one patient had high titres of GAD antibodies (4000 U/ml; nv <1 U/ml). Onconeural antibodies were negative in all, and tumours were not found. Sera 07e223, 06e26,
02e762 were from the Spanish ataxia cohort; all other sera were from the Welsh idiopathic ataxia cohort.
Ab, antibody; ANA, antinuclear antibody; CBA, cell-based assay; NA, not applicable; ND, not determined; Neg, negative; OCB, oligoclonal bands; Pos, positive.
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Movement disordersand sertraline only, with scanning dysarthria and mild ataxia but
able to walk in open spaces. He had monthly temporal partial
seizures but his mood, behaviour and memory were normal. All
the patients were negative for LGI1 antibodies (data not shown).
DISCUSSION
We identiﬁed CASPR2 as an antigenic target in 10% of patients
with idiopathic, cerebellar ataxia. CASPR2 is a transmembrane
protein with a large extracellular domain and is highly expressed
in the axons of the granule neurons of the cerebellum,
14 thus
representing an excellent candidate antigen for cerebellar ataxia.
CASPR2 is essential for the clustering of the VGKC subunits
Kv1.1 and Kv1.2 at juxtaparanodal regions of myelinated axons
and at the axon hillock
15 and recently has been described as one
of the components of the VGKC-complex that is the target for
antibodies in patients with limbic encephalitis, Morvan’s
syndrome and acquired neuromyotonia.
81 6However, in this
study, only one of nine CASPR2-antibody positive patients was
positive by radioimmunoprecipitation for VGKC-complex anti-
bodies. This patient presented with ataxia and also had some
limbic involvement, but none of the other CASPR2-antibody
positive patients had evidence of limbic encephalitis. The lack of
VGKC-complex antibodies in the remaining patients suggests
that CASPR2 antibodies in ataxia may recognise CASPR2
epitopes that are independent of the VGKC-complex. Indeed,
immunostaining of rodent cerebellar tissue shows strong
CASPR2 staining in the cerebellar granule and molecular layers
but not in the strongly Kv1.1-positive cerebellar pinceau.
8 Thus,
CASPR2 may have additional functions in the cerebellum as well
as its established role in juxtaparanodal VGKC clustering, and
the antibodies may bind preferentially to these CASPR2s.
Whether CASPR2 antibodies have a primary pathogenic role
in ataxia, and their mechanisms of action, remain to be
demonstrated. Although three of nine patients had recent onset
of disease, and one of these had full recovery, six patients had
a longer history at sampling; in these patients it is possible that
CASPR2 antibodies represent a secondary phenomenon.
However, lower levels of CASPR2 antibodies might represent the
temporal tail of a higher antibody response present initially,
since many of the newly identiﬁed neurological diseases associ-
ated with antibodies to neuron surface proteins are mono-
phasic.
1 2 There were patients studied here whose serum IgG
bound to cerebellar slices or cultured CGNs but did not bind to
CASPR2 or to VGKC-complexes, VGCCs or GAD. Although we
did not attempt to perform mass spectrometry with these
patients’ sera, it is likely that other antigenic targets could be
identiﬁed in the future. It is therefore important that future
serological studies examine recent-onset patients and look for
antibodies to CASPR2 and other novel antigenic targets.
Immunotherapies could then be applied to those patients in
whom a potentially pathogenic antibody is found, in the hope
that some improvement or stabilisation will occur before
permanent cerebellar damage.
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